Literature DB >> 1275554

[Cellular immunity in melanomalignome (author's transl)].

J Fritz, K Grond, G P Tilz.   

Abstract

Cellular immunological reactivity was examined in 20 patients having melanomalignoma at different clinical stages, using Leukocyte-Migration-Inhibition-Test. As antigens three homologous melanoma-extracts were used, produced by our own method. Independent from the clinical stages cell-migration inhibition could be established in 15 out of the 20 patients. In this way, these tumor extracts have been shown to contain melanoma-associated antigens. Regardless of the clinical stage of the disease, the melanomalignomas patient produces cellular immunity against those tumor-antigens. It is note-worthy that the actual course of the disease seems not to be influenced by immun-mechanisms.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1275554     DOI: 10.1007/BF00558528

Source DB:  PubMed          Journal:  Arch Dermatol Res            Impact factor:   3.017


  23 in total

Review 1.  IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS.

Authors:  M BURNET
Journal:  Br Med Bull       Date:  1964-05       Impact factor: 4.291

2.  Cell-mediated immunity to melanoma-associated antigens in patients with ocular malignant melanoma.

Authors:  D H Char; L Jerome; J L McCoy; R B Herberman
Journal:  Am J Ophthalmol       Date:  1975-05       Impact factor: 5.258

Review 3.  [The immunology of malignant melanoma (author's transl)].

Authors:  G Schieferstein
Journal:  Klin Wochenschr       Date:  1978-03-15

Review 4.  Immunity to neuroblastomas and melanomas.

Authors:  K E Hellström; I Hellström
Journal:  Annu Rev Med       Date:  1972       Impact factor: 13.739

5.  Immunological associations of the halo naevus with cutaneous malignant melanoma.

Authors:  P W Copeman; M G Lewis; T M Phillips; P G Elliott
Journal:  Br J Dermatol       Date:  1973-02       Impact factor: 9.302

6.  In vitro study of cellular immunity against autochthonous human cancer.

Authors:  A Segall; O Weiler; J Genin; J Lacour; F Lacour
Journal:  Int J Cancer       Date:  1972-03-15       Impact factor: 7.396

7.  Cell-mediated immunity in patients with malignant melanoma.

Authors:  R M Mackie; W G Spilg; C E Thomas; A J Cochran
Journal:  Br J Dermatol       Date:  1972-12       Impact factor: 9.302

8.  [Histocompatibility tests prior to transplantations].

Authors:  G P Tilz; S Sailer; R Heschl
Journal:  Wien Z Inn Med       Date:  1969

Review 9.  Microcytotoxicity and serum blocking factors in malignant melanoma and halo nevus.

Authors:  H H Roenigk; S D Deodhar; J A Krebs; B Barna
Journal:  Arch Dermatol       Date:  1975-06

10.  Cellular and humoral immunity against human malignant melanoma.

Authors:  G Fossati; M I Colnaghi; G D Porta; N Cascinelli; U Veronesi
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

View more
  2 in total

1.  [Influence of autologous serum on leucocyte-migration-inhibition-test in melanomalignoma (author's transl)].

Authors:  J Fritz; K Grond
Journal:  Arch Dermatol Res       Date:  1977-04-27       Impact factor: 3.017

2.  Comparative histological studies of regional lymph nodes of 201 melanoma patients. (Microscopic features in relation to individual age, site, and metastatic spread).

Authors:  F Weidner
Journal:  Arch Dermatol Res       Date:  1979-10       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.